Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

2022 | OriginalPaper | Hoofdstuk

22. Infecties (COVID-19)

Auteur: prof. dr. Sabine Oertelt-Prigione

Gepubliceerd in: Gendersensitieve huisartsgeneeskunde

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Geslacht en gender zijn factoren die de immuunrespons beïnvloeden, zodanig dat er potentieel verschillen zijn in de intensiteit en duur van een ontstekingsreactie. Dit hangt samen met verschillen in DNA en hormonen, maar ook in blootstelling aan infectieuze micro-organismen door verschillen in werk, zorg en levensloop. In dit hoofdstuk wordt het voorbeeld van de recente SARS-CoV2/COVID-19-pandemie gebruikt om de invloed te beschrijven van geslacht en gender op infecties in het algemeen. Tegelijkertijd worden het beleid en de behandeling bij COVID-19 beschreven. Het gaat dan om zowel biologische verschillen, zoals in receptorlocatie, hormonale sensitiviteit en immunologische specificiteit, als om sociale verschillen, zoals in blootstelling door genderpatronen in werk, toegankelijkheid van testen en behandeling en langetermijngevolgen.
Literatuur
1.
go back to reference Zavascki AP, Falci DR. Clinical characteristics of Covid-19 in China. N Engl J Med. 2020;382(19):1859. CrossRef Zavascki AP, Falci DR. Clinical characteristics of Covid-19 in China. N Engl J Med. 2020;382(19):1859. CrossRef
2.
go back to reference Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e8. Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e8.
3.
go back to reference Wenham C, et al. Women are most affected by pandemics – lessons from past outbreaks. Nature. 2020;583(7815):194–8. CrossRef Wenham C, et al. Women are most affected by pandemics – lessons from past outbreaks. Nature. 2020;583(7815):194–8. CrossRef
5.
go back to reference Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–8. CrossRef Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–8. CrossRef
6.
go back to reference Esper F, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. 2005;191(4):499–502. CrossRef Esper F, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. 2005;191(4):499–502. CrossRef
7.
go back to reference Sungnak W, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7. CrossRef Sungnak W, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7. CrossRef
8.
go back to reference Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985. Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
9.
go back to reference Channappanavar R, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046–53. CrossRef Channappanavar R, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046–53. CrossRef
10.
go back to reference Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434(7031):400–4. CrossRef Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434(7031):400–4. CrossRef
11.
go back to reference Van der Made CI, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020 Aug 18;324(7):663–73. Van der Made CI, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020 Aug 18;324(7):663–73.
12.
go back to reference Gargaglioni LH, Marques DA. Let’s talk about sex in the context of COVID-19. J Appl Physiol. 2020;128:6. CrossRef Gargaglioni LH, Marques DA. Let’s talk about sex in the context of COVID-19. J Appl Physiol. 2020;128:6. CrossRef
13.
go back to reference Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278–316. CrossRef Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278–316. CrossRef
14.
go back to reference Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res. 2013;162(4):208–18. CrossRef Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res. 2013;162(4):208–18. CrossRef
15.
go back to reference Carrero JJ, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151–64. CrossRef Carrero JJ, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151–64. CrossRef
16.
go back to reference Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466–7. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466–7.
17.
go back to reference Patel JA, et al. Poverty, inequality and COVID-19: the forgotten vulnerable. Public Health. 2020;183:110–1. CrossRef Patel JA, et al. Poverty, inequality and COVID-19: the forgotten vulnerable. Public Health. 2020;183:110–1. CrossRef
18.
go back to reference Abate BB, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10(10):e040129. Abate BB, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10(10):e040129.
19.
go back to reference Christophers B, et al. Trends in clinical presentation of children with COVID-19: a systematic review of individual participant data. Pediatr Res. 2020 Sep 17. Christophers B, et al. Trends in clinical presentation of children with COVID-19: a systematic review of individual participant data. Pediatr Res. 2020 Sep 17.
20.
go back to reference Vandenberg O, et al. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2021 March 19(3)171–83. Vandenberg O, et al. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2021 March 19(3)171–83.
21.
go back to reference Long QX, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8. CrossRef Long QX, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8. CrossRef
22.
go back to reference Group RC, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693–704. Group RC, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693–704.
23.
go back to reference Consortium, W.H.O.S.T., et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497–511. Consortium, W.H.O.S.T., et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497–511.
24.
go back to reference Schiffer V, et al. The “sex gap” in COVID-19 trials: a scoping review. EclinicalMedicine. 2020;29:100652. Schiffer V, et al. The “sex gap” in COVID-19 trials: a scoping review. EclinicalMedicine. 2020;29:100652.
25.
go back to reference Greenhalgh T, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. Greenhalgh T, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.
26.
go back to reference Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220–32. Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220–32.
27.
go back to reference Kim DY, et al. Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020;18(1):7. CrossRef Kim DY, et al. Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020;18(1):7. CrossRef
Metagegevens
Titel
Infecties (COVID-19)
Auteur
prof. dr. Sabine Oertelt-Prigione
Copyright
2022
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2707-2_22